Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways

Summary

Paradoxically, morbid obesity was suggested to protect from cardiovascular co-morbidities as compared to overweight/obese patients. We hypothesise that this paradox could be inferred to modulation ofthe “endocannabinoid” system on systemic and subcutaneous adipose tissue (SAT) inflammation. We designed a translational project including clinical and in vitro studies at Geneva University Hospital. Morbid obese subjects (n=11) were submitted to gastric bypass surgery (GBS) and followed up for one year (post-GBS). Insulin resistance and circulating and SAT levels of endocannabinoids, adipocytokines and CC chemokines were assessed pre- and post-GBS and compared to a control group of normal and overweight subjects (CTL) (n=20). In vitro cultures with 3T3-L1 adipocytes were used to validate findings from clinical results. Morbid obese subjects had baseline lower insulin sensitivity and higher hs-CRP, leptin, CCL5 and anandamide (AEA) levels as compared to CTL. GBS induced a massive weight and fat mass loss, improved insulin sensitivity and lipid profile, decreased C-reactive protein, leptin, and CCL2 levels. In SAT, increased expression of resistin, CCL2, CCL5 and tumour necrosis factor and reduced MGLL were shown in morbid obese patients pre-GBS when compared to CTL. GBS increased all endocannabinoids and reduced adipocytokines and CC chemokines. In morbid obese SAT, inverse correlations independent of body mass index were shown between palmitoylethanolamide (PEA) and N-oleoylethanolamide (OEA) levels and inflammatory molecules. In vitro, OEA inhibited CCL2 secretion from adipocytes via ERK1/2 activation. In conclusion, GBS was associated with relevant clinical, metabolic and inflammatory improvements, increasing endocannabinoid levels in SAT. OEA directly reduced CCL2 secretion via ERK1/2 activation in adipocytes.

Keywords

Endocannabinoids - obesity - subcutaneous adipose tissue - chemokine

^* These authors contributed equally as first authors.

^# These authors contributed equally as last authors.

• References

• 1 Lavie CJ, McAuley PA, Church TS. et al. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 2014; 63: 1345-1354.
• 2 Das SR, Alexander KP, Chen AY. et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011; 58: 2642-2650.
• 3 Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
• 4 Lasselin J, Magne E, Beau C. et al. Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgeryinduced weight loss. J Clin Endocrinol Metab 2014; 99: E53-E61.
• 5 Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-477.
• 6 Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35.
• 7 Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes 2013; 2013: 489187.
• 8 Quercioli A, Pataky Z, Vincenti G. et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369.
• 9 Quercioli A, Montecucco F, Pataky Z. et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 2013; 34: 2063-2073.
• 10 Sugamura K, Sugiyama S, Nozaki T. et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
• 11 Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012; 33: 331-340.
• 12 Quercioli A, Pataky Z, Montecucco F. et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging 2012; 05: 805-815.
• 13 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
• 14 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 15 Thomas A, Hopfgartner G, Giroud C. et al. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009; 23: 629-638.
• 16 Lobo SM, Quinto BM, Oyama L. et al. TNF-β modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine 2012; 60: 150-156.
• 17 Kang M, Yan LM, Li YM. et al. Inhibitory effect of microRNA-24 on fatty acidbinding protein expression on 3T3-L1 adipocyte differentiation. Genet Mol Res 2013; 12: 5267-5277.
• 18 Ge Q, Maury E, Rycken L. et al. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. Int J Obes 2013; 37: 874-880.
• 19 Ambrosino P, Soldovieri MV, Russo C. et al. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARβ agonist palmitoylethanolamide. Br J Pharmacol 2013; 168: 1430-1444.
• 20 Pacher 1 P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J 2013; 280: 1918-1943.
• 21 Godlewski G, Offertáler L, Wagner JA. et al. Receptors for acylethanolamides-GPR55 and GPR119 Prostaglandins Other Lipid Mediat. 2009; 89: 105-111.
• 22 Montecucco F, Di Marzo V, da Silva RF. et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
• 23 Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R. et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776.
• 24 Rodríguez-Calvo R, Serrano L, Coll T. et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2 Diabetes. 2008; 57: 2149-2157.
• 25 Chen B, Wei J, Wang W, Cui G. et al. Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress. Arch Med Res 2009; 40: 241-248.
• 26 Lee HY, Després JP, Koh KK. Perivascular adipose tissue in the pathogenesis of cardiovascular disease. Atherosclerosis 2013; 230: 177-184.
• 27 Azuma K, Katsukawa F, Oguchi S. et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
• 28 Haluzik MM, Lacinova Z, Dolinkova M. et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006; 147: 4517-4524.
• 29 Iqbal N, Seshadri P, Stern L. et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005; 09: 161-165.
• 30 Bluher M, Engeli S, Kloting N. et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
• 31 Cote M, Matias I, Lemieux I. et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007; 31: 692-699.
• 32 Montecucco F, Matias I, Lenglet S. et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-441.
• 33 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
• 34 Martínez de Ubago M, García-Oya I, Pérez-Pérez A. et al. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochim Biophys Acta 2009; 1791: 740-745.
• 35 González-Yanes C, Serrano A, Bermúdez-Silva FJ. et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 2005; 289: E923-E929.
• 36 McClain J, Hsu F, Brown E. et al. Pericardial adipose tissue and coronary artery calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Obesity 2013; 21: 1056-1063.
• 37 Qatanani M, Tan Y, Dobrin R. et al. Inverse regulation of inflammation and mitochondrial function in adipose tissue defines extreme insulin sensitivity in morbidly obese patients. Diabetes 2013; 62: 855-863.
• 38 Arner E, Mejhert N, Kulyté A. et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes 2012; 61: 1986-1993.